Axcan Pharma Inc.
(NDAQ:AXCA) shares rose marginally today after 9.95% holder Pennant
Capital Management said they were disappointed with the $23.35 per
share buyout price by TPG Capital. Shareholders remain divided on the
issue, however, given the fact that the M&A market has suffered a
dramatic setback since the credit crunch, which has lowered valuations
across the board.
"While we support selling the Company, we
believe the valuation indicated is inadequate considering the strong
cash flows of the business coupled with significant net cash on the
balance sheet," said Alan Fournier, managing partner of Pennant. "We
believe the company is worth at least $25 per share using a relatively
conservative 8x EBITDA multiple which still results in a high single
digit FCF yield."
Pennant also questioned the timing of the
deal, pointing out that it was announced concurrently with very strong
revenue and earnings report that, couple with guidance, likely would
have driven a recovery in the stock price. The speculation is that the
deal was announced so that the premium looked much more substantial
than it would have reacted had they waited until after the earnings
report.
In the end, Axcan is a great company that recently
reported strong results. The buyout offer may be ill-timed and
inadequate, but it does represent something that the company should
carefully evaluate. The board should also work to disclose the details
of the process and evaluation to allow shareholders to assess the
fairness of the transaction. Combined, these factors make AXCA a stock
worth watching!
Related CompaniesAxcan Pharma Inc. (AXP)
Salix Pharma Ltd. (SLXP)
Impax Laboratories (IPXL)